The Bayer Pharma Data Science & Artificial Intelligence (DS&AI) F2F meeting in Madrid was a great event! The motto Connect, Clarify & Commit came to life as we connected during networking sessions, breakout sessions and social events. At the poster session we learned about our progress embedding a product mindset and driving operational excellence, closely collaborating with our partners across R&D. We heard presentations, took part in discussions, unconference sessions, asked questions and shared ideas, setting foundations for the growth of DS&AI beyond 2023. The use of POAPs was a definite social success and I am sure you did not miss Jesús’ enthusiasm as he gave an overview of this new tool. By promoting its use, we drive new ways of using this sustainable and effective tool, ultimately helping to innovate its use by doctors, within clinical trials, for patients and more. There were fun elements as well, like the final night, where our very own flash-mob took to the dance floor and we danced until way past midnight! All this was made possible by the org team: Anke Ebert, Larsen Schnadhorst, Kathleen Thies, Sheila Elz, Stefanie Holt-Noreiks and Claudia Vogt. They have done an excellent job coordinating the event, with the perfect balance of presentations, speakers, entertainment, and networking. Now let us make sure we continue to further the impact we have on bringing innovative medicines to our patients. Sai Jasti, Head of DS&AI https://bayer.com/poap

Lucky you! It's not every day that you meet the one and only Hans, leader of the amazing Value, Engagement & Training team, passionately driving digital transformation, strategy, value, portfolio and continuous learning in Bayer Pharma R&D. Situational leadership, empathy, collaboration and transparency are among his core values. In his personal life he runs marathons, trains & coaches a youth football team, works in the garden, walks with his dog and enjoys his Italian/Dutch family. Pleased to meet you :-)

Systems Manager based in London, UK. Currently supporting IMPACT (Clinical Trials Management System), CART (Spotfire reporting) and Gemstone (Veeva). Previous experience with reporting support in Business Objects and Microstrategy. Have been working at Bayer since 2006. Degree in BSc Computer Science.

I met Jesus during the Bayer Data Science & Artificial Intelligence, DS&AI, F2F event in Madrid in May 2023. Jesus works at Bayer AG currently as the Head of Business Disruption. If you are into Stranger Things, Breakthrough Innovations, AcceleRed, TeamRed, Science4Berlin, STEM4Health, Hackathons, Biotech, Digital Health, Startups, Entrepreneurship, Intrapreneurship, Web3, Web5, Networking For Health, Science, Technology, Pharma, Exobiology, Space, Science Fiction, Germany, Cuba, you can connect with Jesus in LinkedIn: https://www.linkedin.com/in/yeysus/ Twitter: https://twitter.com/yeysus Meetup: https://www.meetup.com/members/45080772/ Web3: yeysus.eth/.tez/.near Some of his POAPs collections in Welook.io: Bayer: https://welook.io/0x74839F2fF3bb6F98E5f120329A76A89f52b95DCC/poap/c/1 Corporates: https://welook.io/0x74839F2fF3bb6F98E5f120329A76A89f52b95DCC/poap/c/2 Animated: https://welook.io/0x74839F2fF3bb6F98E5f120329A76A89f52b95DCC/poap/c/5 Ladies: https://welook.io/0x74839F2fF3bb6F98E5f120329A76A89f52b95DCC/poap/c/8 Beautiful: https://welook.io/0x74839F2fF3bb6F98E5f120329A76A89f52b95DCC/poap/c/9 Great connecting with you!

I'm the Chief of staff for DS&AI. I'm the go-to-person for:​ Evolution of our strategy and culture​ Connecting the dots within and across the organization​ Topics you want to present to/discuss with the LT​

Understanding how compounds affect the disease biology of patients, and which potential side effects could be expected, is one of the core challenges in drug discovery. Transcriptomics (RNA-seq) allows us to measure these compound effects via an unbiased readout of gene expression changes. While „conventional“ analysis of RNA-seq data yields insights into individual compound effects and similarities, deeper connections between principles of compound structure and transcriptome effect elude us. Insights into this connection would help us support project teams with data-driven decision making on compounds. In this pilot, we are bringing together a cross-functional team of colleagues from LST, CMD, SyMOL and DS&AI to tackle this challenge and build a toolkit to enable understanding of ​how compound structure relates to complex gene expression patterns​ and to explore common themes amongst structures or shared off-target/general perturbation effects. This toolbox will become the starting point for other efforts aimed at leveraging multi-omics data in understanding compound mechanism of actions. Artwork created using Stable Diffusion.